At the news
? BULLISHIMPACT 7/10 8-K filed Jun 10, 2026 at 17:01 ET
Iovance Biotherapeutics received marketing authorization from the Australian TGA for Amtagvi (lifileucel) for advanced melanoma, marking its third regulatory approval and expanding into a market with the highest global melanoma incidence. Shareholders also approved an increase in authorized common shares from 500M to 650M, providing flexibility for future capital needs.
- Received TGA (Australia) marketing authorization for Amtagvi in advanced melanoma, the company's third global approval
- Australia has the highest rate of melanoma globally with ~17,000 new cases annually
- Shareholders approved increasing authorized common shares from 500M to 650M
- Company is authorizing its first Australian treatment center and advancing expansion strategy
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access